 | Up a level |
Smith, M. R., Parker, C. C., Saad, F., Miller, K., Tombal, B., Ng, Q. S., Boegemann, M., Matveev, V., Piulats, J. M., Zucca, L. E., Heidenreich, A., Kakehi, Y., Zhang, A., Krissel, H., Shen, J., Wagner, V. and Higano, C. (2018). ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Waldschmidt, D., El-Khoueir, A. B., Kim, R. D., Harris, W. P., Sung, M. W., Iqbal, S., Zhang, A., Nakajima, K. and Galle, P. R. (2020). Phase 1b study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). Oncol. Res. Treat., 43 (SUPPL 4). S. 123 - 124. BASEL: KARGER. ISSN 2296-5262